Phase 1/2 Trial of MRTX849 in Combination with TNO155 in Patients with Advanced Solid Tumors with KRAS G12C Mutation

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Advanced Solid Tumors With Kras G12c Mutation
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation. 2) Unresectable or metastatic disease. 3) Presence of a tumor lesion amenable to mandatory biopsy at screening/baseline and on-study unless Sponsor-confirmed as medically unsafe or infeasible or unless Sponsor communicates that sufficient samples have been received. 4) Life expectancy of at least 3 months.

You may not be eligible for this study if the following are true:

  • 1) Active brain metastases. 2) Patients with carcinomatous meningitis. 3) History of significant hemoptysis or hemorrhage within 4 weeks of the first dose date. 4) Undergone major surgery within 4 weeks of first dose date.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.